Kyrollis Attalla has identified TIM-3 and TIGIT as viable targets for monotherapy or in conjunction with other immune checkpoint inhibitors in patients with urothelial cancer of the bladder. The gene discussed is TIGIT; the disease is bladder transitional cell carcinoma.